### Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** More than 22 million Americans suffer from red, itchy, watery eyes caused by allergies, known as allergic conjunctivitis. The common allergens include pollens, dust mites, mold spores, animal dander, perfumes, and food sensitivities. Humidity, temperature, and a patient’s activity are all factors that affect the intensity, frequency, and duration of the allergic response. Activation of the immune response results in the release of inappropriately high amounts of chemical mediators – mainly histamine. These mediators are responsible for the symptoms associated with eye allergies. Allergic conjunctivitis can produce two types of discharge, serous and mucoid. A serous discharge is watery, whereas the mucoid discharge is stringy or ropy. Other symptoms include redness, tearing, swelling, burning, blurred vision, sensitivity to light, or a sensation of fullness in the eyelids. Antihistaminic compounds interact with histamine receptors found on many cells, whereas mast cell stabilizers inhibit degranulation, reducing the allergic response. The American Academy of Ophthalmology (AAO) treatment guidelines recommend an over-the-counter antihistamine/vasoconstrictor agent or use of the more effective second-generation topical histamine H1-receptor antagonists for treatment of mild allergic conjunctivitis. For persistent or frequent symptoms, an agent with mast cell stabilizer activity may be used. Combination antihistamine/mast cell stabilizing agents can be used for either acute or chronic disease. Short courses (1-2 weeks) of ophthalmic corticosteroids may be used to treat disease flares or severe symptoms.

Total program savings for the PDL classes will be regularly reviewed.

<table>
<thead>
<tr>
<th>Program-Specific Information:</th>
<th>Preferred Agents</th>
<th>Non-Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of Criteria:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ Increased risk of ADE</td>
<td>☒ Preferred Drug List</td>
<td></td>
</tr>
<tr>
<td>☐ Appropriate Indications</td>
<td>☐ Clinical Edit</td>
<td></td>
</tr>
<tr>
<td><strong>Data Sources:</strong></td>
<td>☐ Only Administrative Databases</td>
<td>☒ Databases + Prescriber-Supplied</td>
</tr>
</tbody>
</table>

---

*SmartPA PDL Proposal Form © 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries. Other company trademarks are also acknowledged.*
Setting & Population

- Drug class for review: Mast Cell Stabilizers – Ophthalmic
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 1 or more preferred agents
  - Documented trial period of preferred agents
  - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

<table>
<thead>
<tr>
<th>Laboratory Results:</th>
<th>Progress Notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td>MedWatch Form:</td>
<td>Other:</td>
</tr>
</tbody>
</table>

Disposition of Edit

- Denial: Exception Code “0160” (Preferred Drug List)
- Rule Type: PDL

Default Approval Period

- 1 year

References

- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.